Glutamatergic Modulation of Cocaine-related Deficits

Cocaine Dependence Clinical Trial

Official title:

The Effect of Ketamine on Reducing Cue Reactivity in Cocaine Users

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01790490
• Other study ID #: #6162
• Status: Completed
• Phase: Phase 2
• Start date: February 2011
• Est. completion date: March 2012

Study information

• Verified date: April 2019
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human subjects have been unsuccessful to date. The purpose of this investigation is to examine the effects of the NMDAr antagonist ketamine, recently found to have potent therapeutic effects in humans, on cue-induced craving and impaired motivation for quitting cocaine in cocaine dependent participants, 24-hours post-infusion.

Description:

In this study, volunteers will undergo a 9 day inpatient trial during which they will receive three counter-balanced infusions (two doses of ketamine and a dose of lorazepam) on three separate days in a within-subject, double-blind, controlled design. Of the various glutamate antagonists available for human use, ketamine will be utilized because its safety profile, pharmacokinetics, and range of tolerable sub-anesthetic dosings have been very well studied. Also, ketamine has shown promise in managing opiate and alcohol use disorders in certain studies, and may therefore be the most likely glutamate antagonist to dampen cue reactivity and increase motivation in cocaine users. If ketamine significantly improves these deficits, this would suggest that the drug should be investigated further for potential utility as a treatment for cocaine dependence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 52 Years

Eligibility

Inclusion Criteria

1. Active free-base cocaine dependence (at least 4 days of use over the past month, with at least 1 use per week); if the participant uses through another route (IN, IV), then the FB route is dominant (> 80% of occasions).

2. Physically healthy

3. No adverse reactions to study medications

4. 21-52 years of age

5. Normal body weight

6. Responsive to drug cues

7. Capacity to consent

Exclusion Criteria:

1. Seeking treatment or abstinence

2. DSM IV criteria for substance dependence (other than methamphetamine, cocaine, cannabis, or nicotine), or DSM IV criteria for abuse of ketamine or lorazepam

3. DSM-IV criteria for other Axis I psychiatric illness that may make participation hazardous such as schizophrenia, schizoaffective disorder, psychosis NOS, MDD, psychosis secondary to substances, or bipolar disorder

4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders

5. Current suicide risk or a history of suicide attempt within the past 2 years

6. Current use of prescribed psychotropic medication

7. Pregnancy, nursing, or had a baby within the past 6 mo.

8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.

9. Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (>140/90), anemia, active hepatitis or other liver disease, or diabetes

10. "Bad" reaction/experience with prior exposure to ketamine or lorazepam

11. History of significant violence

12. First degree relative with a psychotic disorder

Related Conditions & MeSH terms

• Cocaine Dependence
• Cocaine-Related Disorders

Intervention

Drug:
• Ketamine 0.41 mg/kg
52 minute iv infusion of ketamine 0.41 mg/kg
• Ketamine 0.71 mg/kg
52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
• Lorazepam 2 mg
52 minute infusion of lorazepam 2 mg. This serves as an active control.

Locations

Country	Name	City	State
United States	NYSPI	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Cue Reactivity	Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion.	Baseline and 24 hours after infusion
Primary	Change in Motivation to Quit	Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion. The scores are 0-13, with higher scores indicating greater motivation. The analysis is within-subject. Scores included below are means; higher scores represent higher motivation to quit than do lower scores.	Baseline and 24 hours post-infusion